Literature DB >> 36228257

What is the effect of tumor diameter, lymph node metastases, and SUVmax value on prognosis in limited-stage small cell lung cancer?

Filiz Çimen1, Melike Aloglu1, Sevim Düzgün1, Ayşegül Şentürk1, Şükran Atikcan1, Özlem Özmen2.   

Abstract

OBJECTIVE: This study was designed to investigate the link between survival and prognostic factors such as tumor size, lymph node metastasis, and metabolic activity detected on positron emission tomography/computed tomography in patients with limited-stage small cell lung carcinoma.
METHODS: Patients who were admitted to our hospital with pathological diagnosis of limited-stage small cell lung cancer between January 2015 and December 2019 and were older than 18 years were retrospectively screened.
RESULTS: A total of 77 patients, including 10 females and 67 males, were included in the study. While there were 39 patients over 60 years of age, 38 patients were under 60.The ratios of male patients, N stage, multiple lymph nodes, distant metastasis, brain metastasis, and prophylactic cranial irradiation in the deceased patients' group were significantly (p=0.008, p=0.000, p=0.000, p=0.000, p=0.013, p=0.000, respectively) higher than those in the living patients' group.In the univariate model, we observed that gender, smoking, T stage, N stage, multiple lymph nodes, distant metastasis, brain metastasis, liver metastasis, sequential chemotherapy, sequential radiotherapy, concurrent chemoradiotherapy, and prophylactic cranial irradiation had significant effect (p=0.049, p=0.021, p=0.022, p=0.000, p=0.000, p=0.000 p=0.003, p=0.037, p=0.029, p=0.049, p=0.000, respectively) on survival time. In the multivariate model, smoking, N stage, liver metastasis, and prophylactic cranial irradiation demonstrated significant independent effect (p=0.010, p=0.003, p=0.004, p=0.000, respectively) on survival time.
CONCLUSION: Our findings provide useful information for better patient management, especially in terms of negative factors on the continuation of survival during and after the treatment of limited-stage small cell lung carcinoma patients.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 36228257      PMCID: PMC9575018          DOI: 10.1590/1806-9282.20220325

Source DB:  PubMed          Journal:  Rev Assoc Med Bras (1992)        ISSN: 0104-4230            Impact factor:   1.712


  26 in total

1.  Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline.

Authors:  Charles M Rudin; Giuseppe Giaccone; Nofisat Ismaila
Journal:  J Oncol Pract       Date:  2016-01       Impact factor: 3.840

2.  Prognostic significance of metabolic parameters measured by 18F-FDG PET/CT in limited-stage small-cell lung carcinoma.

Authors:  Hyun Chang; Soo Jin Lee; Jin Lim; Jong Seok Lee; Yu Jung Kim; Won Woo Lee
Journal:  J Cancer Res Clin Oncol       Date:  2019-03-21       Impact factor: 4.553

3.  Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer--what limits limited disease?

Authors:  Patrick Micke; Andreas Faldum; Tsegay Metz; Kai-Michael Beeh; Fernando Bittinger; Jan-Georg Hengstler; Roland Buhl
Journal:  Lung Cancer       Date:  2002-09       Impact factor: 5.705

4.  Prophylactic cranial irradiation in elderly patients with small cell lung cancer: findings from a North Central Cancer Treatment Group pooled analysis.

Authors:  William G Rule; Nathan R Foster; Jeffrey P Meyers; Jonathan B Ashman; Sujay A Vora; Timothy F Kozelsky; Yolanda I Garces; James J Urbanic; Joseph K Salama; Steven E Schild
Journal:  J Geriatr Oncol       Date:  2014-12-04       Impact factor: 3.599

5.  Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer.

Authors:  Ehab M Kamel; Daniel Zwahlen; Matthias T Wyss; Katrin D Stumpe; Gustav K von Schulthess; Hans C Steinert
Journal:  J Nucl Med       Date:  2003-12       Impact factor: 10.057

6.  High tumor metabolic activity as measured by fluorodeoxyglucose positron emission tomography is associated with poor prognosis in limited and extensive stage small-cell lung cancer.

Authors:  Young Joo Lee; Arthur Cho; Byoung Chul Cho; Mijin Yun; Se Kyu Kim; Joon Chang; Jin Wook Moon; In Kyu Park; Hye Jin Choi; Joo-Hang Kim
Journal:  Clin Cancer Res       Date:  2009-03-24       Impact factor: 12.531

7.  Small cell lung cancer.

Authors:  Gregory P Kalemkerian; Wallace Akerley; Paul Bogner; Hossein Borghaei; Laura Qm Chow; Robert J Downey; Leena Gandhi; Apar Kishor P Ganti; Ramaswamy Govindan; John C Grecula; James Hayman; Rebecca Suk Heist; Leora Horn; Thierry Jahan; Marianna Koczywas; Billy W Loo; Robert E Merritt; Cesar A Moran; Harvey B Niell; Janis O'Malley; Jyoti D Patel; Neal Ready; Charles M Rudin; Charles C Williams; Kristina Gregory; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2013-01-01       Impact factor: 11.908

8.  Lymph node micrometastases are associated with disease recurrence and poor survival for early-stage non-small cell lung cancer patients: a meta-analysis.

Authors:  Xu Feng Deng; Li Jiang; Quan Xing Liu; Dong Zhou; Bing Hou; Kefan Cui; Jia Xin Min; Ji Gang Dai
Journal:  J Cardiothorac Surg       Date:  2016-02-16       Impact factor: 1.637

9.  Does surgically resected small-cell lung cancer without lymph node involvement benefit from prophylactic cranial irradiation?

Authors:  Yuqing Lou; Runbo Zhong; Jianlin Xu; Rong Qiao; Jiajun Teng; Yanwei Zhang; Xueyan Zhang; Tianqing Chu; Hua Zhong; Baohui Han
Journal:  Thorac Cancer       Date:  2020-03-06       Impact factor: 3.500

10.  The impact of prophylactic cranial irradiation for post-operative patients with limited stage small cell lung cancer.

Authors:  Meng-Yuan Chen; Xiao Hu; Yu-Jin Xu; Ming Chen
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.